Toshiyuki Seki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshiyuki Seki has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Hirokuni Takano
Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Chiba, Japan
5 shared publications - Aikou Okamoto
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
4 shared publications Aikou Okamoto
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
3 shared publications- Eitaro Suzuki
Department of Obstetrics and Gynecology, The Jikei University Katsushika Medical Center, Tokyo, Japan
3 shared publications Hirokuni Takano
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
3 shared publications- Kyosuke Yamada
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
3 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Impact of platinum-free interval on the efficacy of lenvatinib plus pembrolizumab in advanced or recurrent endometrial cancer
Hamada R, et al. J Gynecol Oncol. 2027 ;38:e31. https://doi.org/10.3802/jgo.2027.38.e31
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessImpact of platinum-free interval on the efficacy of lenvatinib plus pembrolizumab in advanced or recurrent endometrial cancer
Hamada R, et al. J Gynecol Oncol. 2027 ;38:e31. https://doi.org/10.3802/jgo.2027.38.e31
- Open Access
- 23 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 8739
Diagnostic performance of artificial intelligence for detecting peritoneal and small bowel dissemination in epithelial ovarian cancer using preoperative contrast-enhanced CT imaging
In epithelial ovarian cancer (EOC), accurate assessment of the lesions is crucial for determining the appropriate treatment strategy. We evaluated artificial intelligence (AI) for detecting peritoneal and small bowel dissemination in EOC using preoperative contrast-enhanced computed tomography (CT). We retrospectively analyzed 227 patients (254 CT scans) with histologically confirmed ovarian, fallopian tube, or peritoneal carcinoma who underwent surgery between October 2019 and December 2024 at two affiliated institutions. The mean patient age was 56.6 years. The FIGO stage was early in 118 cases and advanced in 136 cases. Histology included serous (n = 123) and non-serous (n = 131). The mean CA125 level and peritoneal cancer index (PCI) score were 2,243.9 U/mL and 5.8, respectively. Two AI models were developed: one for peritoneal dissemination (P-Model) and one for small bowel dissemination (SB-Model). Diagnostic performance was evaluated by sensitivity, specificity, and accuracy. For the P-Model, clinical factors were compared between high- and low-accuracy groups. The P-Model achieved 68.75% sensitivity, 85.84% specificity, and 77.30% accuracy; the SB-Model, 86.40%, 77.47%, and 81.93%, respectively. Low AI accuracy was linked to ascites volume, CA125 level, and PCI score. AI-based analysis of preoperative CT demonstrated favorable diagnostic performance for detecting dissemination in patients with EOC.
- 23 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 8739
Open AccessDiagnostic performance of artificial intelligence for detecting peritoneal and small bowel dissemination in epithelial ovarian cancer using preoperative contrast-enhanced CT imaging
In epithelial ovarian cancer (EOC), accurate assessment of the lesions is crucial for determining the appropriate treatment strategy. We evaluated artificial intelligence (AI) for detecting peritoneal and small bowel dissemination in EOC using preoperative contrast-enhanced computed tomography (CT). We retrospectively analyzed 227 patients (254 CT scans) with histologically confirmed ovarian, fallopian tube, or peritoneal carcinoma who underwent surgery between October 2019 and December 2024 at two affiliated institutions. The mean patient age was 56.6 years. The FIGO stage was early in 118 cases and advanced in 136 cases. Histology included serous (n = 123) and non-serous (n = 131). The mean CA125 level and peritoneal cancer index (PCI) score were 2,243.9 U/mL and 5.8, respectively. Two AI models were developed: one for peritoneal dissemination (P-Model) and one for small bowel dissemination (SB-Model). Diagnostic performance was evaluated by sensitivity, specificity, and accuracy. For the P-Model, clinical factors were compared between high- and low-accuracy groups. The P-Model achieved 68.75% sensitivity, 85.84% specificity, and 77.30% accuracy; the SB-Model, 86.40%, 77.47%, and 81.93%, respectively. Low AI accuracy was linked to ascites volume, CA125 level, and PCI score. AI-based analysis of preoperative CT demonstrated favorable diagnostic performance for detecting dissemination in patients with EOC.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (3)
Molecular and pathological analysis of FOXL2 and TERT promoter mutations in adult-type granulosa cell tumors of the ovary: a study of 64 Japanese patients
Yanagida S, et al. J Gynecol Oncol. 2025 Oct;37:e44. https://doi.org/10.3802/jgo.2026.37.e44
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (3)
Open AccessMolecular and pathological analysis of FOXL2 and TERT promoter mutations in adult-type granulosa cell tumors of the ovary: a study of 64 Japanese patients
Yanagida S, et al. J Gynecol Oncol. 2025 Oct;37:e44. https://doi.org/10.3802/jgo.2026.37.e44
- 16 July 2025
- Published by Elsevier in Gynecologic Oncology
- Vol. 200, 14-21
The detrimental impact of diverting ileostomy on renal function after tumor debulking surgery for advanced ovarian cancer
- 16 July 2025
- Published by Elsevier in Gynecologic Oncology
- Vol. 200, 14-21
The detrimental impact of diverting ileostomy on renal function after tumor debulking surgery for advanced ovarian cancer
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (5)
Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: a multicenter retrospective analysis
Tate S, et al. J Gynecol Oncol. 2025 Mar;36:e80. https://doi.org/10.3802/jgo.2025.36.e80
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (5)
Open AccessBevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: a multicenter retrospective analysis
Tate S, et al. J Gynecol Oncol. 2025 Mar;36:e80. https://doi.org/10.3802/jgo.2025.36.e80
- Open Access
- 18 July 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1078-1083
High cost of chemotherapy for gynecologic malignancies
Background: The prognosis of gynecological malignancies has improved with the recent advent of molecularly targeted drugs and immune checkpoint inhibitors. However, these drugs are expensive and contribute to the increasing costs of medical care. Methods: The Japanese Clinical Oncology Group (JCOG) Health Economics Committee conducted a questionnaire survey of JCOG-affiliated facilities from July 2021 to June 2022 to assess the prevalence of high-cost regimens. Results: A total of 57 affiliated facilities were surveyed regarding standard regimens for advanced ovarian and cervical cancers for gynecological malignancies. Responses were obtained from 39 facilities (68.4%) regarding ovarian cancer and 37 (64.9%) concerning cervical cancer, with respective case counts of 854 and 163. For ovarian cancer, 505 of 854 patients (59.1%) were treated with regimens that included PARP inhibitors, costing >500 000 Japanese yen monthly, while 111 patients (13.0%) received treatments that included bevacizumab, with costs exceeding 200 000 Japanese yen monthly. These costs are ~20 and ~10 times higher than those of the conventional regimens, respectively. For cervical cancer, 79 patients (48.4%) were treated with bevacizumab regimens costing >200 000 Japanese yen per month, ~10 times the cost of conventional treatments. Conclusions: In this survey, >70% of patients with ovarian cancer were treated with regimens that included poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors or bevacizumab; ~50% of patients with cervical cancer were treated with regimens containing bevacizumab. These treatments were ~10 and ~20 times more expensive than conventional regimens, respectively. These findings can inform future health economics studies, particularly in assessing cost-effectiveness and related matters.
- 18 July 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1078-1083
Open AccessHigh cost of chemotherapy for gynecologic malignancies
Background: The prognosis of gynecological malignancies has improved with the recent advent of molecularly targeted drugs and immune checkpoint inhibitors. However, these drugs are expensive and contribute to the increasing costs of medical care. Methods: The Japanese Clinical Oncology Group (JCOG) Health Economics Committee conducted a questionnaire survey of JCOG-affiliated facilities from July 2021 to June 2022 to assess the prevalence of high-cost regimens. Results: A total of 57 affiliated facilities were surveyed regarding standard regimens for advanced ovarian and cervical cancers for gynecological malignancies. Responses were obtained from 39 facilities (68.4%) regarding ovarian cancer and 37 (64.9%) concerning cervical cancer, with respective case counts of 854 and 163. For ovarian cancer, 505 of 854 patients (59.1%) were treated with regimens that included PARP inhibitors, costing >500 000 Japanese yen monthly, while 111 patients (13.0%) received treatments that included bevacizumab, with costs exceeding 200 000 Japanese yen monthly. These costs are ~20 and ~10 times higher than those of the conventional regimens, respectively. For cervical cancer, 79 patients (48.4%) were treated with bevacizumab regimens costing >200 000 Japanese yen per month, ~10 times the cost of conventional treatments. Conclusions: In this survey, >70% of patients with ovarian cancer were treated with regimens that included poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors or bevacizumab; ~50% of patients with cervical cancer were treated with regimens containing bevacizumab. These treatments were ~10 and ~20 times more expensive than conventional regimens, respectively. These findings can inform future health economics studies, particularly in assessing cost-effectiveness and related matters.
- Open Access
- 21 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1069
MR Relaxometry for Discriminating Malignant Ovarian Cystic Tumors: A Prospective Multicenter Cohort Study
Background: Endometriosis-associated ovarian cancer (EAOC) is a well-known type of cancer that arises from ovarian endometrioma (OE). OE contains iron-rich fluid in its cysts due to repeated hemorrhages in the ovaries. However, distinguishing between benign and malignant tumors can be challenging. We conducted a retrospective study on magnetic resonance (MR) relaxometry of cyst fluid to distinguish EAOC from OE and reported that this method showed good accuracy. The purpose of this study is to evaluate the accuracy of a non-invasive method in re-evaluating pre-surgical diagnosis of malignancy by a prospective multicenter cohort study. Methods: After the standard diagnosis process, the R2 values were obtained using a 3T system. Data on the patients were then collected through the Case Report Form (CRF). Between December 2018 and March 2023, six hospitals enrolled 109 patients. Out of these, 81 patients met the criteria required for the study. Results: The R2 values calculated using MR relaxometry showed good discriminating ability with a cut-off of 15.74 (sensitivity 80.6%, specificity 75.0%, AUC = 0.750, p < 0.001) when considering atypical or borderline tumors as EAOC. When atypical and borderline cases were grouped as OE, EAOC could be distinguished with a cut-off of 16.87 (sensitivity 87.0%, specificity 61.1%). Conclusions: MR relaxometry has proven to be an effective tool for discriminating EAOC from OE. Regular use of this method is expected to provide significant insights for clinical practice.
- 21 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1069
Open AccessMR Relaxometry for Discriminating Malignant Ovarian Cystic Tumors: A Prospective Multicenter Cohort Study
Background: Endometriosis-associated ovarian cancer (EAOC) is a well-known type of cancer that arises from ovarian endometrioma (OE). OE contains iron-rich fluid in its cysts due to repeated hemorrhages in the ovaries. However, distinguishing between benign and malignant tumors can be challenging. We conducted a retrospective study on magnetic resonance (MR) relaxometry of cyst fluid to distinguish EAOC from OE and reported that this method showed good accuracy. The purpose of this study is to evaluate the accuracy of a non-invasive method in re-evaluating pre-surgical diagnosis of malignancy by a prospective multicenter cohort study. Methods: After the standard diagnosis process, the R2 values were obtained using a 3T system. Data on the patients were then collected through the Case Report Form (CRF). Between December 2018 and March 2023, six hospitals enrolled 109 patients. Out of these, 81 patients met the criteria required for the study. Results: The R2 values calculated using MR relaxometry showed good discriminating ability with a cut-off of 15.74 (sensitivity 80.6%, specificity 75.0%, AUC = 0.750, p < 0.001) when considering atypical or borderline tumors as EAOC. When atypical and borderline cases were grouped as OE, EAOC could be distinguished with a cut-off of 16.87 (sensitivity 87.0%, specificity 61.1%). Conclusions: MR relaxometry has proven to be an effective tool for discriminating EAOC from OE. Regular use of this method is expected to provide significant insights for clinical practice.
- Open Access
Poor Treatment Outcomes of Locally Advanced Cervical Adenocarcinoma of Human Papilloma Virus Independent Type, Represented by Gastric Type Adenocarcinoma: A Multi-Center Retrospective Study (Sankai Gynecology Study Group)
The revised World Health Organization classification of cervical cancer divides adenocarcinomas into human papillomavirus-associated (HPVa) and -independent (HPVi) types; the HPVi type is represented by the gastric type. The treatment outcomes of locally advanced adenocarcinoma (LaAC), based on this classification, are understudied. We investigated the outcomes of patients with HPVa and HPVi LaACs. Data for all consecutive patients with stage IB3 to IIIC1 adenocarcinoma who received treatment at 12 institutions throughout Japan between 2004 and 2009 were retrieved to analyze progression-free and overall survival. Central pathological review classified 103 and 48 patients as having HPVa and HPVi tumors, respectively. Usual- (84%) and gastric- (90%) type adenocarcinomas were the most frequent subtypes. Surgery was the primary treatment strategy for most patients. Progression-free and overall survival of patients with HPVi were worse than those of patients with HPVa (p = 0.009 and 0.032, respectively). Subgroup analysis by stage showed that progression-free survival was significantly different for stage IIB. The current surgical treatment strategy for LaACs is less effective for HPVi tumors than for HPVa tumors, especially those in stage IIB.
Open AccessPoor Treatment Outcomes of Locally Advanced Cervical Adenocarcinoma of Human Papilloma Virus Independent Type, Represented by Gastric Type Adenocarcinoma: A Multi-Center Retrospective Study (Sankai Gynecology Study Group)
The revised World Health Organization classification of cervical cancer divides adenocarcinomas into human papillomavirus-associated (HPVa) and -independent (HPVi) types; the HPVi type is represented by the gastric type. The treatment outcomes of locally advanced adenocarcinoma (LaAC), based on this classification, are understudied. We investigated the outcomes of patients with HPVa and HPVi LaACs. Data for all consecutive patients with stage IB3 to IIIC1 adenocarcinoma who received treatment at 12 institutions throughout Japan between 2004 and 2009 were retrieved to analyze progression-free and overall survival. Central pathological review classified 103 and 48 patients as having HPVa and HPVi tumors, respectively. Usual- (84%) and gastric- (90%) type adenocarcinomas were the most frequent subtypes. Surgery was the primary treatment strategy for most patients. Progression-free and overall survival of patients with HPVi were worse than those of patients with HPVa (p = 0.009 and 0.032, respectively). Subgroup analysis by stage showed that progression-free survival was significantly different for stage IIB. The current surgical treatment strategy for LaACs is less effective for HPVi tumors than for HPVa tumors, especially those in stage IIB.
- Open Access
- 7 June 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (5) , e62
Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data
Odajima S, et al. J Gynecol Oncol. 2022 Jun;33:e62. https://doi.org/10.3802/jgo.2022.33.e62
- 7 June 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (5) , e62
Open AccessEfficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data
Odajima S, et al. J Gynecol Oncol. 2022 Jun;33:e62. https://doi.org/10.3802/jgo.2022.33.e62
- Open Access
- 23 October 2021
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 38, 100885
A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer
- 23 October 2021
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 38, 100885
Open AccessA case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer